Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 17;4(1):102-109.
doi: 10.1002/epi4.12297. eCollection 2019 Mar.

A genome-wide association study of sodium levels and drug metabolism in an epilepsy cohort treated with carbamazepine and oxcarbazepine

Collaborators, Affiliations

A genome-wide association study of sodium levels and drug metabolism in an epilepsy cohort treated with carbamazepine and oxcarbazepine

Bianca Berghuis et al. Epilepsia Open. .

Abstract

Objective: To ascertain the clinical and genetic factors contributing to carbamazepine- and oxcarbazepine-induced hyponatremia (COIH), and to carbamazepine (CBZ) metabolism, in a retrospectively collected, cross-sectional cohort of people with epilepsy.

Methods: We collected data on serum sodium levels and antiepileptic drug levels in people with epilepsy attending a tertiary epilepsy center while on treatment with CBZ or OXC. We defined hyponatremia as Na+ ≤134 mEq/L. We estimated the CBZ metabolic ratio defined as the log transformation of the ratio of metabolite CBZ-diol to unchanged drug precursor substrate as measured in serum.

Results: Clinical and genetic data relating to carbamazepine and oxcarbazepine trials were collected in 1141 patients. We did not observe any genome-wide significant associations with sodium level in a linear trend or hyponatremia as a dichotomous trait. Age, sex, number of comedications, phenytoin use, phenobarbital use, and sodium valproate use were significant predictors of CBZ metabolic ratio. No genome-wide significant associations with CBZ metabolic ratio were found.

Significance: Although we did not detect a genetic predictor of hyponatremia or CBZ metabolism in our cohort, our findings suggest that the determinants of CBZ metabolism are multifactorial.

Keywords: EpiPGX Consortium; GWAS; adverse effects; antiepileptic drugs; hyponatremia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Manhattan and Q‐Q plots of sodium levels (λ = 1.00)
Figure 2
Figure 2
Manhattan and Q‐Q plots of COIH (λ = 1.00)
Figure 3
Figure 3
Manhattan and Q‐Q plots of carbamazepine metabolic ratio (λ = 0.98)

References

    1. Chung W‐H, Hung S‐I, Hong H‐S, et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature. 2004;428:486. - PubMed
    1. McCormack M, Alfirevic A, Bourgeois S, et al. HLA‐A*3101 and carbamazepine‐induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364:1134–43. - PMC - PubMed
    1. Ozeki T, Mushiroda T, Yowang A, et al. Genome‐wide association study identifies HLA‐A*3101 allele as a genetic risk factor for carbamazepine‐induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011;20:1034–41. - PubMed
    1. Huang C‐C, Chung C‐M, Hung S‐I, et al. Clinical and genetic factors associated with thiazide‐induced hyponatremia. Medicine (Baltimore). 2015;94:e1422. - PMC - PubMed
    1. Berghuis B, de Haan GJ, van den Broek MPH, et al. Epidemiology, pathophysiology and putative genetic basis of carbamazepine‐ and oxcarbazepine‐induced hyponatremia. Eur J Neurol. 2016;23:1393–9. - PubMed